London, June 16, 2026, 15:05 BST
- Haleon hovered near 332p in London, lagging behind FTSE 100 movers. Rothschild & Co Redburn downgraded Haleon to Neutral.
- Haleon repurchased and cancelled 565,285 shares in its latest buyback. Growth questions remain.
- Haleon is due to report H1 2026 results on July 30. That’s the next big date for the company. Investors want to see signs of a rebound in North America and any pick-up in overall volumes.
Haleon PLC shares dropped Tuesday, slipping to the lower ranks of the FTSE 100 after Rothschild & Co Redburn cut its rating and price target. The stock was at 331.7p/331.9p, down 3.30p or 0.98%, according to Hargreaves Lansdown. The FTSE 100 was up 0.71%. MarketScreener showed Haleon around 332.5p on Cboe Europe, off 0.78%. The fresh downgrade is adding to investor concern over Haleon’s sales growth prospects. HL
Haleon shares fell, though the company is still buying back its own stock. On June 15, Haleon said it repurchased 565,285 ordinary shares for cancellation at a volume-weighted average of 331.9552p, bringing voting ordinary shares down to 8.83 billion after the trade settles. Buybacks like this shrink the share count and may lift earnings per share if profits stay steady. The company’s buyback page lists a £500 million 2026 repurchase program that started in March as an on-market plan. Investegate
Haleon shares stayed weak as investors focused more on growth fears than the just-announced buyback. Q1 revenue climbed to £2.86 billion, a 2.2% organic rise after taking out FX and deals. Price increases added 2.4%, but volume and mix dipped 0.2%. A mild cold-and-flu season trimmed about 130 basis points from overall growth. Oral Health stood out, up 8.3% organically with help from Sensodyne and parodontax. Respiratory Health slipped 3.4%. CEO Brian McNamara stuck to the outlook for faster growth through the year and kept full-year guidance unchanged. Haleon Corporate
Guidance is the main driver for the stock now. Haleon is sticking with its organic revenue growth target of 3% to 5% for 2026 and still sees high-single-digit adjusted operating profit growth at constant currency. The adjusted profit strips out what the company sees as one-offs or non-core items, giving investors what they see as a clearer result. In April, Reuters reported Haleon reiterated the 2026 guidance, but with higher freight costs. Organic growth in North America landed at 1%, with Sensodyne and parodontax up, though Reuters pointed out that North America has kept a cap on growth through 2025 because demand has softened and competition increased.
Bulls stay in Haleon for the dependable brand lineup, Oral Health holding up, and margin improvements after productivity moves. There’s still a £500 million buyback helping lift EPS. Analyst views are steady—MarketScreener lists 18 at Outperform, with a price target average of £4.148 against a last close at £3.351. Bears aren’t convinced. Hargreaves Lansdown shows P/E at 18.02, dividend yield 2.14%, so value investors remain on the sidelines. Volumes stalling, North America flat, or no rebound in respiratory leaves little room for error on another miss here. MarketScreener
Haleon trades close to fair value, leaving shares looking fully priced. The buyback and steady brands lend a floor, but Tuesday’s action showed investors aren’t satisfied with just repeated guidance. Next big dates are H1 2026 results on July 30, followed by Q3 on October 29. For July, the street will watch for organic growth in the 3% to 5% band, better volume and mix, plus some lift in North America that isn’t all price-driven. Haleon Corporate
